Groningen, The Netherlands – 1 April 2025 – InnoCore Pharmaceuticals (“InnoCore”), a leading specialist in long-acting injectable (LAI) drug delivery technologies, today announced a new formulation development project with a returning global pharmaceutical partner, building on a successful history of collaboration.
The collaboration leverages InnoCore’s proprietary SynBiosys® technology, a best-in-class, biodegradable polymer platform designed to enable sustained and controlled release of biologics and peptides. The new project will apply the SynBiosys® technology to the customer’s candidate molecule to create a long-acting, in situ forming depot (ISFD) for a peptide-based therapeutic delivering unique competitive differentiation in the field.
Unlike conventional microsphere-based approaches, the in situ forming depot system enables a liquid formulation that transforms into a gel-like depot after injection, forming directly within the target tissue. This depot provides a controlled, sustained release of the peptide over extended periods, ranging from weeks to months, while maintaining the molecule’s bioactivity and structural integrity.
The project aligns with InnoCore’s strategic focus on expanding its leadership in peptide and biologic long-acting formulations, an area of increasing importance across therapeutic segments including endocrinology, immunology, and cardiometabolic disease.
Bart-Jan Korteling, COO at InnoCore Pharmaceuticals, commented: “This new project highlights both the strength of our partnerships and the versatility of our SynBiosys® platform. We’re delighted to work again with this customer and it underscores InnoCore’s growing role as a strategic formulation partner for the world’s leading pharmaceutical and biotechnology companies, while further demonstrating the flexibility and proven performance of its SynBiosys® biodegradable polymer platform.”
With over 20 years of expertise in polymer synthesis, formulation development, and analytical characterization, InnoCore provides fully integrated support from feasibility through clinical scale-up. Its state-of-the-art facilities in Groningen, The Netherlands, are equipped to handle complex polymeric systems, ensuring that even the most challenging active molecules can be translated into robust, long-acting, and patient-friendly injectable therapies.
-Ends-
For more information, please contact:
Notes to Editors
About InnoCore Pharmaceuticals
InnoCore Pharmaceuticals is a leading drug delivery development provider, formulating peptide and biologic APIs into scalable, biodegradable and tunable Long Acting Injectable (LAI) dosage forms.
The Company’s proprietary polymeric drug delivery platform, SynBiosys®, overcomes the significant technical challenges of translating these complex and fragile molecules into LAI drug products that maintain their essential bioactive characteristics.
Dosage forms can be created for early proof of concept, through to clinical trial usage in an easy-to-scale cGMP form. These formulations can be adapted for use in local or systematic injectable forms for a wide range of therapeutic applications, such as osteoarthritis, rheumatology, oncology, CNS, infectious and cardiometabolic diseases.
InnoCore is a true strategic partner to its biopharma customers working hand-in-hand with them to lay strong foundations for future clinical and commercial success. InnoCore is innovating biologic drug formulation for better treatment outcomes and compliance.
For more information, please see: www.innocorepharma.com.